Liquid chromatography-tandem mass spectrometry method as the golden standard for therapeutic drug monitoring in renal transplant

Research output: Contribution to journalArticlepeer-review

Abstract

Kidney transplanted patients need immunosuppressant therapies. Therapeutic drug monitoring approaches produce the optimal clinical outcome is still under debate. This review details strength and limits of methods available: immunoassay and chromatography-based. Liquid chromatography with mass spectrometry detection is a major breakthrough in therapeutic drug monitoring of immunosuppressive agents and is considered as the method of choice in therapeutic drug monitoring (TDM) of immunosuppressants. Despite the initial high cost for the instrumentation, HPLC-MS is more cost effective than microparticle enzyme immunoassay.The main important features of LC-MS/MS methodology for immunosuppressive drugs are the shortened analysis time, an increased throughput, higher selectivity, specificity, and sensitivity, and low cost of analysis.

Original languageEnglish
Pages (from-to)123-126
Number of pages4
JournalJournal of Pharmaceutical and Biomedical Analysis
Volume86
DOIs
Publication statusPublished - 2013

Keywords

  • Immunosuppression
  • Kidney transplantation
  • Liquid chromatography
  • Mass spectrometry
  • Therapeutic drug monitoring

ASJC Scopus subject areas

  • Analytical Chemistry
  • Drug Discovery
  • Pharmaceutical Science
  • Spectroscopy
  • Clinical Biochemistry

Fingerprint Dive into the research topics of 'Liquid chromatography-tandem mass spectrometry method as the golden standard for therapeutic drug monitoring in renal transplant'. Together they form a unique fingerprint.

Cite this